An open-label, non-randomized, single-sequence study to evaluate the effects of DS-8500a on the pharmacokinetics of midazolam in Japanese healthy subjects

Trial Profile

An open-label, non-randomized, single-sequence study to evaluate the effects of DS-8500a on the pharmacokinetics of midazolam in Japanese healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs DS-8500 (Primary) ; Midazolam
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 07 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top